Dr. Seetharamu on Immunotherapy Treatment for Head and Neck Cancers

Nagashree Seetharamu, MD
Published: Tuesday, May 27, 2014

Nagashree Seetharamu, MD, assistant professor, Medicine (Hematology and Medical Oncology), Perlmutter Cancer Center at NYU Langone, discusses the possibility of using immunotherapy agents to treat head and neck cancers.

Seetharamu says she feels that immunotherapy will have a role in head and neck cancers, especially for wildly mutated, HPV-positive tumors.

Since there is currently data for adaptive T cell therapy for EBV-positive nasopharyngeal cancers, Seetharamu believes immunotherapy has a role in patients with nasopharyngeal cancers as well.

Nagashree Seetharamu, MD, assistant professor, Medicine (Hematology and Medical Oncology), Perlmutter Cancer Center at NYU Langone, discusses the possibility of using immunotherapy agents to treat head and neck cancers.

Seetharamu says she feels that immunotherapy will have a role in head and neck cancers, especially for wildly mutated, HPV-positive tumors.

Since there is currently data for adaptive T cell therapy for EBV-positive nasopharyngeal cancers, Seetharamu believes immunotherapy has a role in patients with nasopharyngeal cancers as well.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x